OptimizeRx (NASDAQ:OPRX) Price Target Raised to $24.00 at Citizens Jmp

OptimizeRx (NASDAQ:OPRX) had its price objective boosted by Citizens Jmp from $23.00 to $24.00 in a research report released on Friday,Benzinga reports. Citizens Jmp currently has a market outperform rating on the stock.

Other equities analysts have also recently issued research reports about the company. Citigroup reiterated an “outperform” rating on shares of OptimizeRx in a report on Friday, October 10th. UBS Group set a $23.00 price target on OptimizeRx in a research report on Friday, October 10th. Stifel Nicolaus boosted their price objective on shares of OptimizeRx from $16.00 to $18.00 and gave the company a “buy” rating in a research report on Friday, August 8th. Zacks Research downgraded shares of OptimizeRx from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, October 7th. Finally, JMP Securities lifted their price target on shares of OptimizeRx from $20.00 to $23.00 and gave the stock a “market outperform” rating in a research note on Friday, October 10th. Nine equities research analysts have rated the stock with a Buy rating, four have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $14.45.

OptimizeRx Price Performance

Shares of OptimizeRx stock traded down $3.29 during trading hours on Friday, reaching $15.65. The company’s stock had a trading volume of 1,013,794 shares, compared to its average volume of 372,301. The firm has a 50 day moving average price of $18.87 and a 200-day moving average price of $15.10. The company has a debt-to-equity ratio of 0.21, a current ratio of 2.57 and a quick ratio of 2.57. The stock has a market cap of $290.54 million, a P/E ratio of -28.98 and a beta of 1.24. OptimizeRx has a one year low of $3.78 and a one year high of $22.25.

OptimizeRx (NASDAQ:OPRX) last announced its quarterly earnings results on Thursday, November 6th. The company reported $0.20 EPS for the quarter, beating analysts’ consensus estimates of $0.03 by $0.17. OptimizeRx had a negative net margin of 9.42% and a positive return on equity of 4.50%. The firm had revenue of $26.07 million during the quarter, compared to the consensus estimate of $23.83 million. OptimizeRx has set its FY 2026 guidance at EPS. FY 2025 guidance at EPS. On average, analysts predict that OptimizeRx will post -0.33 EPS for the current year.

Insider Transactions at OptimizeRx

In related news, CEO Stephen L. Silvestro sold 1,620 shares of the firm’s stock in a transaction dated Friday, October 3rd. The shares were sold at an average price of $18.75, for a total value of $30,375.00. Following the transaction, the chief executive officer owned 188,916 shares of the company’s stock, valued at $3,542,175. This trade represents a 0.85% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Patrick D. Spangler sold 11,120 shares of OptimizeRx stock in a transaction dated Thursday, August 28th. The shares were sold at an average price of $17.49, for a total transaction of $194,488.80. Following the sale, the director owned 44,215 shares of the company’s stock, valued at $773,320.35. The trade was a 20.10% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Corporate insiders own 5.60% of the company’s stock.

Institutional Investors Weigh In On OptimizeRx

A number of hedge funds and other institutional investors have recently bought and sold shares of OPRX. Blair William & Co. IL boosted its holdings in OptimizeRx by 4.9% in the 1st quarter. Blair William & Co. IL now owns 631,031 shares of the company’s stock valued at $5,465,000 after purchasing an additional 29,648 shares during the last quarter. Rhumbline Advisers raised its position in shares of OptimizeRx by 10.5% during the 1st quarter. Rhumbline Advisers now owns 27,785 shares of the company’s stock valued at $241,000 after buying an additional 2,636 shares during the period. Whetstone Capital Advisors LLC lifted its holdings in OptimizeRx by 11.7% in the first quarter. Whetstone Capital Advisors LLC now owns 1,508,303 shares of the company’s stock valued at $13,062,000 after acquiring an additional 157,880 shares during the last quarter. Nuveen LLC purchased a new position in OptimizeRx in the first quarter worth approximately $455,000. Finally, Parkman Healthcare Partners LLC purchased a new position in OptimizeRx in the first quarter worth approximately $4,114,000. Hedge funds and other institutional investors own 76.47% of the company’s stock.

OptimizeRx Company Profile

OptimizeRx Corporation, a digital health technology company, enables care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. It offers various tech-enabled marketing solutions through its Artificial Intelligence-generated Dynamic Audience and Activation Platform, which enables customers to execute traditional marketing campaigns on its proprietary digital point-of-care network, as well as dynamic marketing campaigns that optimize audiences in real time to increase the value of treatment information for healthcare professionals and patients in response to clinical care events.